TY - JOUR
T1 - Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
AU - Herweijer, Eva
AU - Leval, Amy
AU - Ploner, Alexander
AU - Eloranta, Sandra
AU - Simard, Julia Fridman
AU - Dillner, Joakim
AU - Netterlid, Eva
AU - Sparén, Pär
AU - Arnheim-Dahlström, Lisen
PY - 2014
Y1 - 2014
N2 - Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
AB - Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
KW - Condylomata Acuminata: epidemiology
KW - Condylomata Acuminata: prevention & control
KW - Papillomavirus Infections: prevention & control
KW - Papillomavirus Vaccines: administration & dosage
KW - Registries: statistics & numerical data
KW - Sweden: epidemiology
KW - Uterine Cervical Neoplasms: prevention & control
KW - Vaccination: statistics & numerical data
U2 - 10.1001/jama.2014.95
DO - 10.1001/jama.2014.95
M3 - Article
C2 - 24519299
SN - 1538-3598
VL - 311
SP - 597
EP - 603
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 6
ER -
